The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 6, 2006, Pages 743-749

  Targownik, L E ^a,b   Al Mamfud, A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEMOGRAPHY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HIGH RISK POPULATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROTON PUMPS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33644749150     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02829.x     Document Type: Review

References (30)

1. The World Health Organization Statistical Information Service (WHOSIS) Global Burden of Disease Estimates 2002., accessed 12 December 2005.q3
2. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 2002 324 71
3. Goldstein RE Andrews M Hall WJ Moss AJ for the Multicenter Myocardial Ischemia Research Group Marked reduction in long-term cardiac deaths with aspirin after a coronary event J Am Coll Cardiol 1996 28 326
4. Pearson TA Blair SN Daniels SR et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee Circulation 2002 106 388
5. Hennekens CH Dyken ML Fuster V Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association Circulation. 1997 96 2751 3
6. Centers for Disease Control and Prevention (CDC) Prevalence of aspirin use to prevent heart disease - Wisconsin, 1991, and Michigan, 1994 MMWR Morb Mortal Wkly Rep 1997 46 498 502
7. Derry S Loke YK Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis BMJ 2000 321 1183
8. Weisman SM Graham DY Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events Arch Intern Med 2002 162 2197
9. Kahaleh M Vinciane M Mulkay J-P Arvanitaki M Buset M Preoperative esophagogastroduodenoscopy in patients undergoing cardiac surgery Gastroenterology 2001 120 A233
10. Yeomans ND Lanas AI Talley NJ et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin Aliment Pharmacol Ther 2005 22 795 801
11. Fries JF Williams CA Bloch DA Michel BA Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models Am J Med 1991 91 213 22
12. Griffin MR Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury Am J Med 1998 104 23S 9S
13. Rockall TA Logan RFA Devlin HB Northfield TC Incidence of and mortality from acute upper gastrointestinal hemorrhage in the UK BMJ 1995 311 222 26
14. Katschinski BD Logan RFA Davies J Langman MJS Audit of mortality in upper gastrointestinal bleeding Postgraduate Medical Journal 1989 65 913 7
15. Rockall TA Logan RFA Devlin HB Northfield TC Risk assessment after acute upper gastrointestinal hemorrhage Gut 1996 38 316 21
16. Lanas A Perez-Aisa MA Feu F et al. Investigators of the Asociacion Espanola de Gastroenterologia (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use Am J Gastroenterol 2005 100 1685 93
17. Lai KC Lam SK Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use N Engl J Med 2002 346 2033 8
18. Chan FK Ching JY Hung LC et al. Clopidogrel vs. aspirin and esomeprazole to prevent recurrent ulcer bleeding N Engl J Med 2005 352 238 44
19. Ibanez L Vidal X Vendrell L Moretti U Laporte JR Upper gastrointestinal bleeding associated with antiplatelet drugs Aliment Pharmacol Ther 2006 23 235 42
20. Cryer B Feldman M Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans Gastroenterology 1999 117 17 25
21. Abraham HS El-Serag HB Johnson ML National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs Gastroenterology 2005 129 1171 8
22. Sturkenboom MC Burke TA Dieleman JP et al. Underutilization of preventive strategies in patients receiving NSAIDs Rheumatology (Oxford) 2003 42 Suppl. 3 iii23 31
23. Harrington RA Becker RC Ezekowitz M et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 2004 126 513S
24. Lanas A Sekar MC Hirschowitz BI Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding Gastroenterology 1992 103 862 9
25. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Arthritis Rheum 2000 43 1905 15
26. Lanza FL A guideline for the treatment and prevention of NSAID induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology Am J Gastroenterol 1998 93 2037 46
27. Robinson MG Griffin JW Jr. Bowers J et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs Dig Dis Sci 1989 34 424 8
28. Ehsanullah RS Page MC Tildesley G Wood JR Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine BMJ 1988 297 1017 21
29. Graham DY Agrawal NM Roth SH Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial Lancet 1988 2 1277 80
30. Hawkey CJ Karrasch JA Szczepanski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole vs. Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group N Engl J Med 1998 338 727 34